Sagimet Biosciences Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Unaudited. Financial amounts below are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Business context
Sagimet is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors. Its lead candidate, oral denifanstat, is being studied for nonalcoholic steatohepatitis (NASH). The company had no approved products and reported no product or licensing revenue.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $4.676 | $6.371 | $9.163 | $12.234 |
| General and administrative expense | $2.381 | $0.867 | $4.659 | $3.747 |
| Total operating expenses / operating loss | $7.057 / $(7.057) | $7.238 / $(7.238) | $13.822 / $(13.822) | $15.981 / $(15.981) |
| Net loss | $(6.785) | $(7.102) | $(13.372) | $(15.837) |
| Net cash used in operating activities | Not provided for quarter | Not provided for quarter | $(12.804) | $(10.803) |
Gross margin and product margins are not applicable because the company had no revenue. At June 30, 2023, cash and cash equivalents were $18.508 million, with no short-term marketable securities; current assets were $21.354 million and current liabilities were $5.287 million. Total liabilities were $5.292 million, including lease and warrant liabilities; the company reported no outstanding debt obligations.
Six-month investing cash inflow of $32.200 million came from sales of marketable securities. Financing cash outflow was $1.046 million, principally IPO-related deferred financing costs. Cash was $158,000 at December 31, 2022; the increase to $18.508 million was therefore not generated by operations.
Changes versus prior comparable periods
- Q2 net loss narrowed by $0.317 million year over year; six-month net loss narrowed by $2.465 million.
- R&D expense fell 27% in Q2 and 25% for the six-month period. Management attributed the decline mainly to lower FASCINATE-2 trial costs as patients progressed, partly offset by other clinical, preclinical, and personnel costs.
- G&A expense rose by $1.514 million in Q2 and $0.912 million for the six-month period, reflecting higher stock compensation, staffing, and IPO-related professional costs. The six-month comparison also reflects $1.4 million of prior-year IPO costs that had been expensed in 2022.
- Operating cash use increased to $12.804 million from $10.803 million for the first six months, despite the lower net loss.
Outlook, developments, and key risks
- Management expected topline liver-biopsy results from the FASCINATE-2 Phase 2b NASH trial in Q1 2024. It cited previously reported interim results in 52 patients after 26 weeks, including an approximately 34% reduction in liver fat and a 67% responder rate; these interim findings are not final and may change.
- The filing says IPO proceeds and June 30 cash were expected to fund operations for at least 12 months from the August 21, 2023 financial-statement issuance date. Elsewhere, the risk discussion says the IPO proceeds and cash were expected to fund operations through the end of 2024. Both are estimates based on assumptions; the filing cautions that actual spending or development needs may shorten the runway.
- After quarter-end, the July 18 IPO issued 5,312,500 Series A shares at $16.00 per share, for $96.4 million gross proceeds and approximately $86.2 million net proceeds. Outstanding preferred stock converted into common stock. A 1-for-79.4784 reverse stock split took effect July 7, 2023; historical share and per-share figures were adjusted retrospectively.
- After quarter-end, Sagimet invoiced Ascletis for a $2.0 million net development milestone related to a Phase 3 recurrent glioblastoma trial, payable before the end of August 2023. The filing reported no revenue recognized for it as of June 30. The Greater China license also provides for up to $122 million in aggregate development and commercial milestones and tiered royalties; these are contingent, not guaranteed proceeds. Ascletis assigned its license rights and obligations to affiliate Gannex in July 2023, while remaining responsible for performance.
- Management reported prior modest COVID-related trial enrollment delays. Principal risks include dependence on denifanstat, uncertain clinical and regulatory outcomes, future financing needs, patient enrollment, third-party clinical and manufacturing reliance, competition, and intellectual-property protection. The company has no internal manufacturing capability.
- In an oncology Phase 1 trial, five patients experienced six serious pneumonitis episodes, one fatal; the investigator assessed the event as at least possibly related to both denifanstat and paclitaxel. The filing reported no serious adverse events assessed as drug-related in the NASH trials to date. The company stated it did not then hold product-liability insurance.
- The filing reported disclosure controls and procedures were effective as of June 30, 2023, with no material change in internal control over financial reporting during the quarter. No material legal proceedings were reported.
Important facts for investors to verify
- Review final FASCINATE-2 biopsy results against the interim biomarker findings and confirm the timing and interpretation of the announced topline data.
- Confirm receipt and accounting treatment of the $2.0 million Ascletis milestone, and assess the development and commercial progress under the Gannex-assigned Greater China license.
- Track cash burn, spending plans, and any updated runway estimates against the post-IPO cash position and stated development milestones.
- Assess potential dilution from equity awards and future financing, and the effects of the post-IPO share structure. The filing reported 21,354,999 Series A shares outstanding at August 16, 2023 and approximately 59% beneficial ownership by executive officers, directors, principal stockholders, and affiliates.
- Verify the cover-page response indicating “No” to having filed all required reports during the preceding 12 months, and consider the context and any subsequent clarification.